GlobeNewsWire · REGN · November 18, 2026
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗